Mammowave

To detect breast cancer when it can be cured

Focusing on persons’ well-being, our solution is non-ionizing (free from X-rays), meaning there is no radiation risk

Microwave Imaging

MammoWave is made of an aluminium cylindrical hub, containing two antennas that operate in the microwave band (1-9 GHz) at a very low power (1mW). MammoWave allows to illuminate the breast using an electromagnetic fields and to measure the correspondent scattered fields. The measured fields is then processed field through a dedicated algorithm, obtaining the image of the breast. Microwave imaging exploits the contrast in the dielectric properties at microwave frequencies of normal tissues and tissues with lesions. MammoWave software uses a novel, fast, and accurate imaging algorithm (based on the Huygens Principle) which highlights tissues dielectric inhomogeneities.

MammoWave benefits

Accuracy

MammoWave is a highly accurate screening device with high sensitivity and high specificity, regardless of tissue density. MammoWave performance in detecting breast lesions are enhanced through AI-Artificial Intelligence

Affordability and Simplicity

With low setup and running costs, MammoWave can transform your clinic offering to a more people-centric screening that is innovative and cost-effective. MammoWave 's imagining technology is operator independent

For all women, any time

MammoWave can be used in asymptomatic population without any safety restriction such as age or frequency of use. MammoWave is the perfect solution for a complementary use with respect to traditional devices to assist in reducing the risk of missing lesions in asymptomatic population

Comfort

A breast scan is completed whilst the person is in a horizontal face down position on a thin mattress, with each breast, in turn, placed in a soft cup. MammoWave removes the need for applying pressure on the breast or any liquid to be applied, making it a painless, dry and comfortable experience for the person

Clinical Trials

The first MammoWave feasibility clinical trials ended in March 2020.

The trials, authorized by Italian Ministry of Health and by the Ethical Committee of Regione Umbria, Italy, have been carried out at Perugia Hospital “Azienda Ospedaliera S. Maria della Misericordia” (clinical investigator: Dr. Michele Duranti) and at Foligno Hospital (clinical investigator: Dr. Riccardo Loretoni).

Thanks to the H2020 SMEINST Phase 2 funding, in 2021 UBT completed an interational multicentric trials at the following Hospitals: Humanitas Milano (clinical investigator: Dr. Chiara Bernardi); San Martino Genova (clinical investigator: Dr. Alberto Tagliafico and Dr. Massimo Calabrese); Toledo Hospital (clinical investigator: Dr. Cristina Romero) in Spain. Clinical trials results have been published in numerous scientific journals.

Images of some test cases can be found here

Performances when using AI can be found here.